Biothera Pharmaceuticals, Inc. is advancing Imprime PGG, a unique cancer immunotherapy, through Phase 2 clinical trials in multiple cancer indications in combination with checkpoint inhibitor therapy. While cancers can actively avoid detection by the immune system, Imprime PGG works as an immunological “ignition switch” to trigger a cascade of responses throughout the innate immune system that culminate in T cell activation. Imprime PGG synergizes with immune checkpoint inhibitors that unleash tumor killing by activated T cells. Studies in more than 500 subjects, including more than 400 cancer patients, have demonstrated strong evidence of tolerability and signals of activity in multiple combinations and tumor types. Patient recruitment is underway for studies in triple negative breast cancer, head and neck cancer and non-small cell lung cancer. Significant milestones, including response, safety and biomarker data, are expected through 2018-19.
About Biothera Pharmaceuticals
For Healthcare Professionals
Steven O’Day, M.D. talks about the potential synergies of combining Imprime PGG and checkpoint inhibitor therapy in Biothera Pharmaceuticals’ Phase 2 melanoma/triple negative breast cancer study. Dr. O’Day, Professor of Medical Oncology and Director of Immuno-Oncology and Clinical Research, The John Wayne Cancer Institute at Providence Saint John’s Health Center, is a Principal Investigator for this study and Chairman of the Trial Steering Committee overseeing the clinical trial. Other brief videos about the study protocol, Imprime PGG’s mechanism of action and a patient selection biomarker are designed for medical professionals seeking additional information about Biothera’s clinical development program.
Biothera Pharmaceuticals was recently featured in BioWorld Today, which reported on the Company’s unique PAMP technology, clinical development plans with checkpoint inhibitors and path to FDA approval for Imprime PGG. Learn More
Biothera Pharmaceuticals and its research collaborators are currently seeking patients for clinical studies evaluating Imprime PGG and pembrolizumab (KEYTRUDA®) in the following indications:
- Metastatic triple negative breast cancer
- Squamous cell carcinoma of the head and neck
- Non small cell lung cancer
In addition, a biomarker that may identify patients with the best probability of responding to the developmental therapy is being utilized in the triple negative breast cancer and head and neck cancer studies. Learn More
Biothera Pharmaceuticals has partnered with leading pharmaceutical companies and research organizations to advance Imprime PGG and cancer immunotherapy. We have clinical research collaborations with Merck, Genentech and AstraZeneca to evaluate Imprime PGG and checkpoint inhibitor (PD-1/PD-L1) therapies in multiple indications.